Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 24, 2026
YieldMax MSTR Option Income Strategy ETF (MSTY) Falls -15% in 30 Days as Strategy Inc. (MSTR) Breaks Its Bitcoin 'Never Sell' Streak

YieldMax MSTR Option Income Strategy ETF (MSTY) Falls -15% in 30 Days as Strategy Inc. (MSTR) Breaks Its Bitcoin 'Never Sell' Streak

Key Takeaways

  • MSTY declined approximately 15% over the last 30 days, extending a quarterly drop of roughly 51% as the fund's underlying exposure to MSTR remained under severe pressure.
  • Strategy Inc. (MSTR) sold Bitcoin for the first time since 2022 to cover preferred stock dividend obligations, shattering the "never sell" narrative and triggering a cascade of selling across its equity and options complex.
  • Bitcoin recorded its worst June in four years, falling 20% for the month, while record outflows from spot Bitcoin ETFs compounded downward pressure on crypto-linked assets.
  • A hawkish Federal Reserve, elevated real yields, and geopolitical disruptions in the Middle East created a challenging macro environment for risk assets broadly.
  • MSTY's weekly distributions have shrunk alongside declining option premiums, with recent payouts dropping from above $0.50 per share earlier in the quarter to approximately $0.15–$0.21.

Understanding the YieldMax MSTR Option Income Strategy ETF (MSTY) and Its Exposure

The YieldMax MSTR Option Income Strategy ETF (MSTY) is an actively managed exchange-traded fund that seeks to generate current income while providing indirect exposure to the share price of Strategy Inc., formerly MicroStrategy (MSTR). Rather than holding MSTR shares directly, the fund employs a synthetic covered call strategy—selling call options on MSTR and collecting option premiums—while collateralizing those positions with U.S. Treasury bills and cash equivalents. The fund carries an expense ratio of 1.03% and manages approximately $710 million in assets under management.

MSTY holds roughly 41 securities, with its top holdings dominated by short-duration U.S. Treasury bills and MSTR put and call options. Treasury bills typically represent 25–30% of the portfolio as collateral, while the options book reflects the fund's core income-generation engine. Because MSTY does not invest directly in MSTR, its performance is driven by the interplay of option premiums collected and the price movement of MSTR through the synthetic exposure. When MSTR declines sharply, the fund's net asset value falls in parallel, and the income from option writing cannot fully offset those capital losses—a dynamic that has defined MSTY's recent trajectory. I also checked this using Tickeron’s AI Screener to compare MSTY’s metrics against other option-income ETFs in the sector.

MSTY Price Performance: -15% Over the Last 30 Days and -51% for the Quarter

Over the last 30 days, MSTY fell approximately 15%, declining from $14.69 to $12.47. The move was not a single-day shock but rather a continuation of a persistent downtrend punctuated by sharp selloffs in mid-to-late June and again in mid-July. The quarterly picture is considerably steeper: from roughly $25.27 in late April to $12.47, MSTY shed about 51% of its value. The decline has been trend-driven rather than range-bound, with each minor bounce met by renewed selling pressure as MSTR's underlying fundamentals continued to deteriorate.

What Drove MSTY’s Moves Over the Past 30 Days

The dominant catalyst behind MSTY's 30-day decline was the unraveling of Strategy Inc.'s leveraged Bitcoin treasury model. Between June 29 and July 5, MSTR sold 3,588 Bitcoin for approximately $216 million—the first material Bitcoin liquidation by the company since 2022. The sales were executed to fund preferred stock dividend obligations, which exceed $1.5 billion annually. This broke the foundational narrative that Strategy would never sell its Bitcoin holdings, sending MSTR shares from the $136 area in mid-June to as low as $82 by late June.

MSTR subsequently sold 4.82 million Class A common shares for $466.7 million to boost its U.S. dollar reserve to $3.0 billion, further diluting equity holders. Bitcoin itself fell roughly 20% in June—its worst month in four years—driven by record outflows from U.S. spot Bitcoin ETFs, a hawkish Federal Reserve holding rates at 3.50–3.75%, and hotter-than-expected PCE inflation at 4.1%. The Crypto Fear & Greed Index hit 10, deep in "Extreme Fear" territory. Because MSTY's synthetic covered call strategy is intrinsically tied to MSTR's price and volatility, the fund's NAV fell in near-lockstep with MSTR's decline, while weekly distribution amounts contracted from above $0.50 per share to roughly $0.15–$0.21 as option premiums shrank alongside falling implied volatility and lower strike prices. From what I see, the contraction in distributions highlights how sensitive the fund remains to volatility levels.

Drivers Behind MSTY’s -51% Quarterly Decline

The quarterly decline of approximately 51% reflects a broader unraveling of the crypto-equity complex that began in May 2026. Bitcoin, which had briefly recovered above $82,000 in mid-May, reversed sharply as the Federal Reserve's hawkish pivot under new Chair Kevin Warsh pushed real yields higher and the U.S. dollar strengthened. The US-Iran conflict and the closure of the Strait of Hormuz drove Brent crude above $120 per barrel, lifting May CPI to 4.2% year-over-year and extinguishing hopes for near-term rate cuts.

For MSTR specifically, the stock's premium to its net asset value collapsed from above 1.8x to roughly 0.99x, meaning the market no longer assigned any premium to Strategy's Bitcoin acquisition model. With Bitcoin trading below MSTR's average acquisition cost of approximately $75,476 per coin, the company's treasury sat underwater, producing a $14.46 billion unrealized loss on digital assets in Q1 2026. MSTR's Q1 EPS came in at -$38.25. As MSTR declined roughly 55% over the quarter, MSTY's synthetic exposure transmitted those losses directly to fund shareholders, while the weekly distribution engine—dependent on elevated volatility and rich option premiums—steadily weakened.

MSTY ETF Outlook: Factors to Monitor Going Forward

The trajectory of MSTY over the coming months will be primarily determined by three interconnected factors. First, Bitcoin's price path remains paramount. Any sustained recovery above the $65,000–$70,000 range would relieve pressure on MSTR's balance sheet and potentially restore the mNAV premium, lifting both MSTR shares and MSTY's NAV. Conversely, a break below the $54,000 realized-price level could force additional Bitcoin liquidations by Strategy, introducing structural selling pressure that would cascade into MSTY.

Second, the Federal Reserve's July 29 policy decision and forward guidance will shape the macro backdrop for risk assets. If cooling energy prices translate into lower inflation readings, rate-hike expectations may fade, potentially reviving inflows into Bitcoin ETFs and crypto-linked equities. Third, MSTY's distribution sustainability depends on a stabilization—if not recovery—in MSTR's share price and implied volatility. The fund's high distribution rate of over 80% has been largely composed of return of capital, meaning that sustained NAV erosion could compress future payouts further. Investors should monitor weekly distribution declarations, MSTR's Q2 earnings report, Bitcoin ETF flow data, and any additional Bitcoin sales disclosed in Strategy's 8-K filings with the SEC. I’m watching this closely as volatility patterns evolve.

Using Tickeron’s AI Tools in My Research Process

When analyzing complex option-income products like MSTY, I often turn to Tickeron’s AI-powered platforms to cross-reference technical signals, volatility trends, and peer comparisons. These tools help surface relevant data points efficiently without replacing my own fundamental review. In particular, Tickeron’s AI Screener has proven useful for scanning ETF holdings and option strategies across sectors, allowing me to place MSTY’s recent performance in a broader context while monitoring for potential stabilization signals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MSTY

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for MSTY turns positive, indicating new upward trend

MSTY saw its Momentum Indicator move above the 0 level on August 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator turned positive. In of the 38 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MSTY's RSI Indicator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MSTY just turned positive on July 06, 2026. Looking at past instances where MSTY's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MSTY advanced for three days, in of 139 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MSTY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MSTY broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MSTY entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks current income; the fund’s secondary investment objective is to seek exposure to the share price of the common stock of MicroStrategy Incorporated d/b/a Strategy, subject to a limit on potential investment gains. The fund is an actively managed ETF that seeks current income while maintaining the opportunity for exposure to the share price of the common stock of MicroStrategy Incorporated, subject to a limit on potential investment gains. The fund is non-diversified.
View a ticker or compare two or three
MSTY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Derivative Income
Address
United States
Phone
N/A
Web
N/A
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.